RxDoctor Payments Data

Jeremiah Schnoor, MD

Internal Medicine · Marshall, MINPI 1437476355

Payments from drug & device makers

$205in general payments, 2019–2025

Across 14 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$45
  • Astellas Pharma US Inc$36
  • Amarin Pharma, Inc.$27
  • Boehringer Ingelheim$23
  • GSK$19
  • Amgen$18
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$205 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$113,170
Medicare patients
352
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$157,352
XareltoRivaroxaban111$109,296
OzempicSemaglutide91$103,368
FarxigaDapagliflozin Propanediol87$86,439
JanuviaSitagliptin Phosphate34$40,072
JardianceEmpagliflozin52$36,610
TrulicityDulaglutide15$20,268
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$17,214
MyrbetriqMirabegron16$14,537
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$13,819
Atorvastatin Calcium897$13,105
Combivent RespimatIpratropium/Albuterol Sulfate11$9,348
Omeprazole416$9,035
Spiriva RespimatTiotropium Bromide14$8,947
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$8,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$157,352137 claims
Johnson & JohnsonXarelto$45$109,296111 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$23$54,90577 claims
Astellas Pharma US IncMyrbetriq$36$14,53716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Marshall

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →